Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PETTA, Salvatore
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.939
EU - Europa 12.418
AS - Asia 11.805
SA - Sud America 1.977
AF - Africa 332
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 21
Totale 51.538
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.576
SG - Singapore 4.517
RU - Federazione Russa 3.436
CN - Cina 2.928
IT - Italia 2.682
BR - Brasile 1.572
DE - Germania 1.530
FI - Finlandia 1.196
HK - Hong Kong 1.196
VN - Vietnam 1.058
PL - Polonia 779
FR - Francia 564
GB - Regno Unito 510
UA - Ucraina 429
IE - Irlanda 395
JP - Giappone 376
BD - Bangladesh 369
IN - India 303
KR - Corea 249
CA - Canada 182
AR - Argentina 157
SE - Svezia 155
NL - Olanda 150
RO - Romania 135
TR - Turchia 134
AT - Austria 111
MX - Messico 109
IQ - Iraq 108
BE - Belgio 80
ZA - Sudafrica 73
ES - Italia 70
CI - Costa d'Avorio 64
ID - Indonesia 63
SA - Arabia Saudita 57
EC - Ecuador 52
PK - Pakistan 47
CO - Colombia 46
UZ - Uzbekistan 46
PH - Filippine 44
IR - Iran 42
AU - Australia 40
MA - Marocco 38
MY - Malesia 38
EG - Egitto 35
PY - Paraguay 34
VE - Venezuela 34
KE - Kenya 33
CL - Cile 31
GR - Grecia 29
DK - Danimarca 27
AE - Emirati Arabi Uniti 24
CH - Svizzera 23
NP - Nepal 22
TN - Tunisia 22
AZ - Azerbaigian 21
JM - Giamaica 21
JO - Giordania 20
CZ - Repubblica Ceca 19
DZ - Algeria 18
LT - Lituania 17
PE - Perù 17
TH - Thailandia 17
BG - Bulgaria 16
AL - Albania 15
BO - Bolivia 15
KZ - Kazakistan 15
LB - Libano 15
IL - Israele 14
KG - Kirghizistan 14
UY - Uruguay 14
EU - Europa 10
GE - Georgia 10
OM - Oman 10
BY - Bielorussia 9
NG - Nigeria 9
CR - Costa Rica 8
DO - Repubblica Dominicana 7
MD - Moldavia 7
MM - Myanmar 7
NI - Nicaragua 7
SN - Senegal 7
ET - Etiopia 6
HN - Honduras 6
NZ - Nuova Zelanda 6
QA - Qatar 6
XK - ???statistics.table.value.countryCode.XK??? 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BN - Brunei Darussalam 5
GT - Guatemala 5
MO - Macao, regione amministrativa speciale della Cina 5
PA - Panama 5
PS - Palestinian Territory 5
RS - Serbia 5
SD - Sudan 5
TG - Togo 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
BA - Bosnia-Erzegovina 4
CY - Cipro 4
GA - Gabon 4
Totale 51.476
Salva come PNG Salva come JPEG
Città #
Singapore 3.250
Fairfield 3.109
Ashburn 3.007
Woodbridge 1.492
Chandler 1.351
San Jose 1.344
Seattle 1.236
Houston 1.226
Wilmington 1.161
Hong Kong 1.127
Cambridge 1.075
Ann Arbor 711
Zgierz 689
Palermo 633
Moscow 591
Beijing 450
Medford 439
Helsinki 411
Los Angeles 400
Dublin 391
Des Moines 390
Ho Chi Minh City 368
New York 356
Secaucus 353
Tokyo 339
Altamura 338
Lauterbourg 328
Cologne 327
Santa Clara 310
Council Bluffs 305
Princeton 278
Dallas 266
Hanoi 260
Nanjing 258
Lawrence 254
Frankfurt am Main 220
Jacksonville 217
Hefei 189
San Diego 168
Chicago 154
Boardman 145
The Dalles 135
São Paulo 131
Buffalo 129
Rome 127
Milan 120
Nuremberg 102
Jinan 100
London 98
Shenyang 94
Ludwigshafen am Rhein 91
Orem 90
Dearborn 85
Changsha 81
Tulsa 76
Nanchang 74
Tianjin 72
Hebei 69
Lappeenranta 67
Warsaw 66
Phoenix 65
Abidjan 64
Zhengzhou 63
Chennai 62
Jiaxing 60
Amsterdam 57
Brussels 57
Columbus 56
Shanghai 56
Atlanta 55
Denver 53
Guangzhou 51
Izmir 51
Brooklyn 50
Hangzhou 47
Paris 47
Haiphong 45
Munich 44
Saint Petersburg 44
San Paolo di Civitate 44
Seongnam 44
Johannesburg 43
Baghdad 42
Da Nang 42
Manchester 41
Mumbai 40
Redwood City 40
Seoul 40
Vienna 40
Rio de Janeiro 39
Montreal 37
Central 36
Tashkent 36
Belo Horizonte 35
Ningbo 35
Toronto 35
Falls Church 32
Boston 31
Brasília 31
Nairobi 31
Totale 33.544
Salva come PNG Salva come JPEG
Nome #
"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV" 1.256
Diet, Weight Loss, and Liver Health in NAFLD: Pathophysiology, Evidence and Practice 521
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 388
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 334
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 324
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis 307
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 306
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 303
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 301
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 299
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease 298
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 296
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 295
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 292
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 284
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 278
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 271
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 270
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 269
L’insulino-resistenza è il principale fattore indipendente correlato con l’aumentato rischio metabolico nelle donne affette da PCOS 266
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 262
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 262
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 259
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 258
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 255
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 253
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women 253
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 252
The Hepatic Expression of Vitamin D Receptor is Inversely Associated with the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. 250
The cheating liver: imaging of focal steatosis and fatty sparing 250
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 248
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 246
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 246
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 245
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 245
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study 245
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 244
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 244
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 242
MAFLD: a multisystem disease 239
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver 239
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 238
MERTK rs4374383 polymorphism affects the severity of fibrosis in nonalcoholic fatty liver disease 237
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 235
Metabolic Factors and Chronic Hepatitis C: A Complex Interplay 235
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis 234
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 229
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 229
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 226
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 226
Genetic background in nonalcoholic fatty liver disease: A comprehensive review 226
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 225
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 220
Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease 220
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 218
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 218
STORIA NATURALE DELLA CIRROSI EPATICA 217
LIPIDOMICS OF FATTY LIVER IN NAFLD AND HCV INFECTION: LIVER SPHYNGOLIPIDS AND FATTY ACIDS 217
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 216
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 213
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. 211
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 211
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 209
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 208
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. 207
Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome 206
qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis 201
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 200
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 197
Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies 196
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C 194
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent 194
AISF position paper on HCV in immunocompromised patients 194
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 193
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 193
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 193
Statin use and non-alcoholic steatohepatitis in at risk individuals 192
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 192
Liver stiffness quantification in patients with non-alcoholic steatohepatitis: comparison of shear wave elastography and transient elastography with liver biopsy correlation 191
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C 190
Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with Nonalcoholic fatty liver disease 190
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 190
Hepatic expression of cyclooxygenase-2 in non alcoholic fatty liver disease 189
Cardiovascular diseases and HCV infection: a simple association or more? 189
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage 189
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. 189
Metformina e pioglitazone in soggetti affetti da diabete mellito tipo 2 con steatosi epatica 188
Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. 188
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values 187
Hyperuricemia in non-alcoholic fatty liver disease: authors' reply. 186
Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. 185
Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis 185
Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population 185
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis 183
Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study) 183
Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. 182
Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe? 182
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 182
A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B 182
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 182
Totale 24.362
Salva come PNG Salva come JPEG
Categoria #
all - tutte 186.237
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 186.237
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021856 0 0 0 0 0 0 0 0 0 0 485 371
2021/20223.283 164 561 119 92 75 149 145 348 391 386 248 605
2022/20234.455 496 944 80 427 416 650 315 330 462 44 208 83
2023/20242.002 79 291 113 137 169 514 239 108 31 63 57 201
2024/20255.938 165 311 465 550 184 277 400 354 421 697 863 1.251
2025/202622.053 1.288 957 1.353 2.114 2.225 3.243 3.290 2.352 1.966 2.078 1.187 0
Totale 53.331